BioSpace News Archive

Career Advice

The Do’s and Don’ts to Remember When Writing a Professional Email

Oh, the world of professional email communication. It can be hard to navigate with various expectations across industries, age groups and cultures.

November 5, 2020
·
3 min read
·
Laura Brothers
Policy

FDA Places New CMC Demands on bluebird’s Sickle Cell Treatment

The company announced late Wednesday that its sickle cell disease gene therapy treatment will not be submitted to the U.S. Food and Drug Administration for two more years.

November 5, 2020
·
2 min read
·
Alex Keown
Policy

Logistics and Efficacy Challenges Force World to Pivot Against COVID-19

When it comes to a novel virus like SARS-CoV2, a certain amount of “rolling with the punches” is required, and governments and global organizations like the World Health Organization are beginning to dismiss certain treatments and devote themselves wholeheartedly to others.

November 5, 2020
·
2 min read
·
Heather McKenzie
Business

BioSpace Movers & Shakers, Nov. 6

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

November 5, 2020
·
7 min read
·
Alex Keown
Business

Can Pharma Win Back America?

According to recent polls, less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal.

November 5, 2020
·
4 min read
·
Kate Goodwin
Potential MS Therapy Shows Promising Efficacy, Avoids Immune Suppression

Researchers from the Thomas Jefferson University have designed an antigen-specific therapy for the autoimmune disease multiple sclerosis (MS) using oligodendrocyte-derived extracellular vesicles.

November 5, 2020
·
3 min read
·
Brandon May
Drug Development

Research Roundup: Why Blood Clots in COVID-19 and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

November 5, 2020
·
5 min read
·
Mark Terry
Q3 Reports: AbbVie, BMS, Allogene, Gilead and AstraZeneca

It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.

November 5, 2020
·
6 min read
·
Mark Terry
Business

SPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies

Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.

November 5, 2020
·
4 min read
·
Gail Dutton
Genetown

Do Waning COVID-19 Antibodies Mean Loss of Immunity?

Harvard immunology experts comment on studies regarding antibodies in COVID-19 patients diminishing over time.

November 5, 2020
·
5 min read
·
Kate Goodwin